

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Voluntary Operational Update

Manufacturing and Supply Agreement for Senstend™

This announcement is made on a voluntary basis by the board (the “**Board**”) of directors (the “**Director(s)**”) of Regent Pacific Group Limited (the “**Company**”) and collectively with its subsidiaries, the “**Group**”) to inform the shareholders of the Company and potential investors of the following update in respect of its operations.

The Board is pleased to announce that our commercial strategic partner 江蘇萬邦生化醫藥集團有限責任公司 (Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.) (“**Wanbang Biopharmaceutical**”, a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (“**Fosun**”)), 江蘇萬邦醫藥營銷有限公司 (Wanbang Pharmaceutical Marketing and Distribution Co., Ltd) (“**Wanbang MKT**”, an affiliate of Wanbang Biopharmaceutical), Genetic S.p.A. (“**Genetic**”) and Plethora Solutions Limited (“**Plethora**”, the Company’s wholly-owned subsidiary) have entered into the manufacturing and supply agreement (the “**Agreement**”) after market close today whereby Genetic will, pursuant to the terms of the Agreement, manufacture and supply Senstend™ to Wanbang Biopharmaceutical for the market in The People’s Republic of China (“**China**” or “**PRC**”). The Agreement is for an initial term of 5 years and thereafter will automatically renew for further successive two-year periods unless terminated.

The signing of this Agreement removes a significant hurdle in the China regulatory approval process as it will allow Wanbang Biopharmaceutical to complete the filing of the New Drug Application (“**NDA**”) registration dossier with the National Medical Products Administration (“**NMPA**”), with approval expected within 12 months from filing. Under the terms of the Agreement, Wanbang Biopharmaceutical will as soon as practicable but in any event no later than 3 months of receipt of the manufacturing information, file the NDA with NMPA.

Jamie Gibson, CEO of the Group, said “*We are delighted that this Agreement has been signed as it unlocks the last remaining hurdle for filing the NDA with NMPA. We now look forward to our commercial partner in China submitting the NDA to NMPA imminently with approval expected within 12 months from filing.*”

About Senstend™

Senstend™ (the brand name for Fortacin™ in China) is a proprietary formulation of two marketed drugs, lidocaine and prilocaine, dispensed by a metered dose aerosol developed for the treatment of premature ejaculation (“PE”), a disorder affecting between 20% and 30% of men in China. Based on World Bank population estimates of 2022, there is a significant target male PE population base of approximately 55 million males in China (assuming 20% PE prevalence and aged between 20-59 years old). In December 2018, Plethora signed an exclusive license agreement with Wanbang Biopharmaceutical to market Senstend™ for PE in China.

Jamie Gibson, further, said, *“It is estimated that Senstend™ has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, growing to over 170 million patients by its tenth year. Our strong partner Wanbang Biopharmaceutical, which is part of the Fosun network, has an established marketing expertise, e-commerce platforms and an unrivalled nationwide logic and distribution through Sinopharm Group Co. Ltd., China’s number one pharmaceutical and healthcare distributor, through its network of hospitals, clinics and pharmacies to ensure the commercial success of Senstend™ in China.”*

All costs of the clinical trials, including all other associated regulatory and submission costs are being met by Wanbang Biopharmaceutical. If the NMPA grants an import licence for Senstend™, US\$5 million (or approximately HK\$39 million) (before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US\$2 million (or approximately HK\$15.60 million) (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. In addition, and as disclosed in the Company’s announcement on 3 December 2018, there are other significant payments payable to the Group from Wanbang Biopharmaceutical in respect of:

Commercial Milestone Payment

A possible payment of up to US\$25 million (or approximately HK\$195 million) in total upon achievement of certain annual net sales milestones, dependent on the net sales achieved by Wanbang Biopharmaceutical.

Further Payments and Royalties

- 25% of net receipts; and
- tiered percentage royalties on net sales, ranging from the low to high teens, except that lower payment structures will apply in certain circumstances where a generic product has successfully entered and impacted the market in China.

To the best of the Directors' knowledge, information and belief, and having made all reasonable enquiries, each of Wanbang Biopharmaceutical, Wanbang MKT, Genetic and their ultimate beneficial owners are independent third parties of the Company and its connected person(s) ascribed to it in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The signing of the Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 26 August 2024

As at the date of this announcement, the Board comprises six Directors:

Executive Director:

Jamie Gibson (*Chief Executive Officer*)

Non-Executive Directors:

James Mellon (*Chairman*)

Jayne Sutcliffe

Independent Non-Executive Directors:

Mark Searle

Adrian Chan

Ihsan Al Chalabi